Dennis R Burton

This inventor holds 55 USPTO granted patents and 16 published patent applications, plus 7 CIPO patents and 10 EPO patents, primarily in HIV Antibody Research. Top assignees: Scripps Research Institute, International Aids Vaccine Initiative, Theraclone Sciences, Inc.. Active years: 1997-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis R Burton. Retrieved from https://idiyas.com/inventor/dennis-r-burton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 55 (Patent Applications = 16)

% Patents Active = 72.7

CIPO Patents = 7 (Patent Applications = 12)

EPO Patents = 10 (Patent Applications = 23)

Average Co-Inventor Count = 4.9

ph-index = 13

Forward Citations = 659(Granted Patents)

Forward Citations (Not Self Cited) = 620(Dec 10, 2025)

Company Filing History:

51 out of 1,208

Scripps Research Institute

patents

20 out of 71

International Aids Vaccine Initiative

patents

14 out of 28

Theraclone Sciences, Inc.

patents

4. 4 out of 16,025

University of California

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

7. 2 out of 1,328

Texas A&M University System

patents

8. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2026

Loading Chart...

Areas of Expertise:

HIV-1

Monoclonal Antibodies

Broadly Neutralizing Antibodies

Trimeric Glycoproteins

Immunogens

B Cell Receptor

Antibody Libraries

Nucleic Acids

Respiratory Syncytial Virus

Dengue Virus

Ligand Capture Assay

Prion Proteins

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715907 - RAPID ELICITATION OF BROADLY NEUTRALIZING BOVINE ANTIBODIES TO HIV ENV (2026-08-25),

2. 12679869 - RECOMBINANT HIV ENV POLYPEPTIDES AND THEIR USES (2026-07-14),

3. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

4. 12398177 - SIV envelope trimer (2025-08-26),

5. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

6. 12241081 - B cell receptor modification in B cells (2025-03-04),

7. RE50268 - Broadly neutralizing antibody and uses thereof (2025-01-14),

8. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

9. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

10. 11795211 - Rapid elicitation of broadly neutralizing antibodies to HIV Env (2023-10-24),

11. 11767347 - HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations (2023-09-26),

12. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

13. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

14. RE49037 - Broadly neutralizing antibody and uses thereof (2022-04-18),

15. 11236134 - Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations (2022-02-01),

Title: Dennis R. Burton: A Pioneer in HIV Research and Antibody Development

Introduction

Dennis R. Burton, based in La Jolla, California, is a renowned inventor with an impressive portfolio of 49 patents. His work primarily focuses on the development of broadly neutralizing antibodies, particularly in the context of HIV research. Burton's innovative contributions have significantly advanced the fields of immunology and virology, providing new avenues for the prevention and treatment of HIV infections.

Latest Patents

Among Dennis R. Burton's latest patents are groundbreaking inventions aimed at combating HIV. The first, titled "Broadly neutralizing antibody and uses thereof," discusses an exceptionally broad and potent neutralizing antibody. This invention covers cross-clade neutralizing activity of 83% at a median inhibitory concentration of 0.003 μg/ml, providing compositions containing this antibody and their various uses.

Another notable patent addresses "Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity." This invention outlines a method for obtaining broadly neutralizing antibodies (bNabs) by screening memory B cell cultures and cloning cells exhibiting broad neutralization. The resultant monoclonal antibodies selectively bind to epitopes from the envelope proteins and inhibit the infection of HIV-1 species across various clades. Moreover, this patent includes details on generating human monoclonal anti-HIV antibodies for prophylaxis, diagnosis, and treatment of HIV infections, highlighting immunization methods using conserved epitopes.

Career Highlights

Dennis R. Burton has made significant career strides while affiliated with esteemed institutions such as The Scripps Research Institute and the International Aids Vaccine Initiative. His dedication to research and innovation has positioned him at the forefront of HIV antibody development, earning him a reputation as a leading figure in the field.

Collaborations

Throughout his career, Burton collaborated with notable colleagues, including Sanjay K. Phogat and Wayne C. Koff. These partnerships have facilitated groundbreaking research efforts, enhancing the understanding and treatment of HIV through innovative antibody technologies.

Conclusion

Dennis R. Burton's unparalleled contributions to immunology and virology through his 49 patents underscore his commitment to advancing scientific knowledge and healthcare. His work on broadly neutralizing antibodies not only broadens our understanding of HIV infection but also provides promising avenues for future treatments and preventive measures against the virus.

Profile summary based on public USPTO records.